Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China.
Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China.
复制标题
DOI：
10.1186/1756-0500-7-65
复制
发表时间：
2014-01-30
影响因子：
1.8
通讯作者：
Wang G
中科院分区：
文献类型：
--
作者：
Zhang ZX;Chen H;Chen SD;Shao M;Sun SG;Qu QM;Zhang BR;Liu YM;Xu Q;Wan X;Li L;Wen HB;Chen X;Chen HB;Liu ZG;Wang J;Wang G
中国帕金森病（PD）的临床特点和治疗尚不清楚。在2006年12月至2007年5月期间，对中国四个城市经济区域的42所随机选择的大学附属医院的901名PD患者进行了临床特征、药物使用和运动并发症的大型横断面调查。901例PD患者年龄30 ~ 88岁，中位病程50个月。大多数（737,81.8%）使用左旋多巴（中位数为375毫克/天），并经常添加低剂量的其他抗帕金森药物。在左旋多巴治疗的患者中，运动并发症的患病率很低（运动障碍：8.5%；运动波动：18.6%），即使在病程≥11年的患者中（运动障碍：18.1%；运动波动：42.2%）。较高的左旋多巴使用与较高的运动障碍发生率（OR 2.44; 95% CI 1.20-5.13）和运动波动（OR 2.48; 95% CI 1.49-4.14）相关。单独使用左旋多巴治疗PD （OR 0.46; 95% CI 0.22-0.95）或与其他药物联合治疗PD （OR 0.41; 95% CI 0.19-0.87）与非左旋多巴治疗相比，运动障碍的发生率较低。中国PD患者多采用低剂量左旋多巴和添加低剂量抗帕金森药物治疗，运动并发症发生率低，可能受中国文化的影响。
Little is known about the clinical features and treatment of Chinese patients with Parkinson disease (PD). A large cross-sectional survey of clinical features, medication use, and motor complications was conducted in 901 consecutive PD patients, from 42 randomly selected university-affiliated hospitals in four urban economic regions of China, between December 2006 and May 2007. The 901 PD patients had age range 30 to 88, and median disease duration 50 months. Most (737, 81.8%) used L-dopa (median 375 mg/day), and often added low doses of other antiparkinsonian agents. Among L-dopa-treated patients, the prevalence of motor complications was low (dyskinesias: 8.5%; motor fluctuations: 18.6%), even among patients with disease duration ≥11 years (dyskinesias: 18.1%; motor fluctuations: 42.2%). Higher L-dopa use was associated with higher occurrence of dyskinesias (OR 2.44; 95% CI 1.20-5.13) and motor fluctuations (OR 2.48; 95% CI 1.49-4.14). Initiating PD treatment with L-dopa alone (OR 0.46; 95% CI 0.22-0.95) or in combination with other medications (OR 0.41; 95% CI 0.19-0.87) was associated with less dyskinesia than treatment initiated with non-L-dopa medication. Many Chinese PD patients are treated with low-dose L-dopa and added low-dose antiparkinsonian agents, with a low prevalence of motor complications, which might be influenced by Chinese culture.